Newcastle University, Newcastle upon Tyne, UK.
Royal College of Surgeons in Ireland, Dublin, Ireland.
Cancer Med. 2024 Feb;13(3):e6937. doi: 10.1002/cam4.6937. Epub 2024 Jan 19.
In oestrogen-receptor positive breast cancer, daily oral adjuvant endocrine therapy (ET) for at least 5 years significantly reduces risks of recurrence and breast cancer-specific mortality. However, many women are poorly adherent to ET. Development of effective adherence support requires comprehensive understanding of influences on adherence. We undertook an umbrella review to identify determinants of ET adherence.
We searched PubMed, Embase, CINAHL, PsycINFO, Cochrane and PROSPERO (inception to 08/2022) to identify systematic reviews on factors influencing ET adherence. Abstracted determinants were mapped to the World Health Organization's dimensions of adherence. Reviews were quality appraised and overlap assessed.
Of 5732 citations screened, 17 reviews were eligible (9 quantitative primary studies; 4 qualitative primary studies; 4 qualitative or quantitative studies) including 215 primary papers. All five WHO dimensions influenced ET non-adherence: The most consistently identified non-adherence determinants were patient-related factors (e.g. lower perceived ET necessity, more treatment concerns, perceptions of ET 'cons' vs. 'pros'). Healthcare system/healthcare professional-related factors (e.g. perceived lower quality health professional interaction/relationship) were also important and, to a somewhat lesser extent, socio-economic factors (e.g. lower levels of social/economic/material support). Evidence was more mixed for medication-related and condition-related factors, but several may be relevant (e.g. experiencing side-effects, cost). Potentially modifiable factors are more influential than non-modifiable/fixed factors (e.g. patient characteristics).
The evidence-base on ET adherence determinants is extensive. Future empirical studies should focus on less well-researched areas and settings. The determinants themselves are numerous and complex in indicating that adherence support should be multifaceted, addressing multiple determinants.
在雌激素受体阳性乳腺癌中,每日口服辅助内分泌治疗(ET)至少 5 年可显著降低复发和乳腺癌特异性死亡风险。然而,许多女性对 ET 的依从性较差。开发有效的依从性支持措施需要全面了解影响依从性的因素。我们进行了一项伞式综述,以确定 ET 依从性的决定因素。
我们检索了 PubMed、Embase、CINAHL、PsycINFO、Cochrane 和 PROSPERO(从成立到 2022 年 8 月),以确定影响 ET 依从性的系统评价。将摘录的决定因素映射到世界卫生组织的依从性维度。对综述进行了质量评估和重叠评估。
在筛选出的 5732 条引文中有 17 条综述符合条件(9 项定量主要研究;4 项定性主要研究;4 项定性或定量研究),其中包括 215 篇主要论文。五个世界卫生组织维度均影响 ET 不依从:最一致确定的不依从决定因素是患者相关因素(例如,较低的 ET 必要性感知、更多的治疗担忧、对 ET 的“弊端”与“好处”的看法)。医疗保健系统/医疗保健专业人员相关因素(例如,感知到的较低质量的医疗专业人员互动/关系)也很重要,在某种程度上,社会经济因素(例如,较低的社会/经济/物质支持水平)也是如此。药物相关和疾病相关因素的证据更为混杂,但有几个可能相关(例如,出现副作用、费用)。可修改的因素比不可修改的/固定的因素更具影响力(例如,患者特征)。
ET 依从性决定因素的证据基础广泛。未来的实证研究应集中在研究较少的领域和环境。决定因素本身数量众多且复杂,表明依从性支持应该是多方面的,需要解决多个决定因素。